Sparks - QBiotics

QBiotics has reported final results from the Phase II QB46C-H08 trial of intratumoural tigilanol tiglate in patients with head and neck cancer refractory to standard care. The treatment achieved a 78% objective response rate in injected tumours, with 14 of 18 evaluable lesions showing complete or partial ablation based on best observed response. Six injected tumours were completely ablated, and none recurred while the patients remained on study, with follow-up extending to five months. At the patient level, 64% of response-evaluable participants (9/14) achieved complete or partial ablation of a treated tumour or tumour segment, meeting the primary efficacy endpoint. All 16 treated patients were included in the safety analysis, with adverse events mainly comprising expected local effects such as pain, swelling and tumour necrosis. The results support continued clinical development of tigilanol tiglate in head and neck cancer, where next steps may include larger studies, longer follow-up and/or further evaluation of its potential role alongside existing treatments.